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pDITORIAL COMMENT
polipoprotein A-I and
igh-Density Lipoprotein
s This the Beginning of the
ra of Noninvasive Angioplasty?*
hristie M. Ballantyne, MD, FACC,†
ijay Nambi, MD‡
ouston, Texas
he quest for finding new therapies to alter the natural
istory of atherosclerotic cardiovascular disease (ASCVD)
nvolves a series of steps that provide insight into the
athophysiology, leading to new targets for therapy. For
xample, interventions to lower low-density lipoprotein
holesterol (LDL-C) have become an established approach
or the prevention and treatment of ASCVD on the basis of
ecades of research that included epidemiologic studies,
haracterization of naturally occurring genetic defects in
umans, genetic mutations in animals, experimental studies
hat altered LDL-C levels in animals, and finally random-
zed clinical trials in humans. Advances in these areas
sually occur simultaneously and contribute to our under-
tanding of the disease process, ultimately resulting in
mproved therapies.
See page 1429
Decades of information from large clinical studies have
stablished that a low level of high-density lipoprotein
holesterol (HDL-C) is a risk factor for ASCVD (1).
nimal studies have shown that infusion of HDL can slow,
rrest, or in some cases regress the process of atherosclerotic
laque formation (2). An improved understanding of the
etabolism of HDL has helped elucidate probable mecha-
isms by which HDL decreases the progression of athero-
clerosis and hence offers potential targets for drug devel-
pment.
Apolipoprotein (apo) A-I, which is synthesized by the
iver and intestine, is the most abundant HDL protein and
lays a major role in HDL metabolism. The nascent
holesterol-poor HDL particle containing apo A-I acquires
holesterol and phospholipids from peripheral cells, facili-
ated by adenosine triphosphate-binding cassette protein-1,
hus initiating a process known as reverse cholesterol trans-
ort. The enzyme lecithin:cholesterol acyltransferase then
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Center for Cardiovascular Disease Prevention, Methodist DeBakey
eart Center, Section of Atherosclerosis, and ‡Section of Cardiology, Department of
edicine, Baylor College of Medicine, Houston, Texas. Dr. Ballantyne receivesfesearch support and is a consultant for Pfizer.sterifies the unesterified cholesterol within the HDL par-
icle, and the esterified cholesterol is taken up by the liver
hrough scavenger receptor class type BI. In addition, the
holesteryl ester in HDL can be exchanged for triglycerides
rom other lipoproteins through the action of the cholesteryl
ster transfer protein (CETP). Other actors in this complex
etabolic pathway include phospholipid transfer protein
nd various lipases (lipoprotein, hepatic, and endothelial).
n addition to reverse cholesterol transport, HDL also may
onfer protection against atherosclerosis by preventing oxi-
ation of LDL, promoting the availability of nitric oxide,
nd modulating expression of endothelial cell adhesion
olecules.
Some studies have suggested that apo A-I may be a better
arker of ASCVD than total cholesterol and HDL-C,
articularly after statin therapy (3). Animal studies have
uggested that interventions modulating apo A-I will likely
educe the burden of atherosclerosis (4,5). Several naturally
ccurring mutations of apo A-I have been described in
umans. Low HDL-C levels and premature atherosclerosis
ave been described in humans with the complete deletion
f the APOAI gene (6,7).
In this issue of the Journal, Hovingh et al. (8) describe a
ew APOAI mutation, L178P, which was associated with an
ncreased risk for atherosclerosis as assessed by increased
arotid intimal-medial thickness (IMT), impaired flow-
ediated dilation (FMD), and increased premature coro-
ary artery disease (CAD) events. They initially identified
ix probands, all from the same geographic region of the
etherlands, with a point mutation in the APOAI gene that
esulted in the substitution of a proline for the usual leucine
esidue at position 178. Six kindred with 54 heterozygotes
or the mutation and 147 family controls were identified.
he APOAI gene defect was associated with a 52% mean
eduction in apo A-I levels and a 62% decrease in HDL
evels (17 vs. 47 mg/dl). Median FMD was noted to be
ignificantly reduced in patients with the mutation after
tatistical correction for the significant age difference be-
ween the groups. Similarly, carotid IMT was increased in
atients carrying the mutation compared with controls. The
ncrease in IMT with this mutation in apo A-I was similar
o the increase in IMT observed in familial hypercholester-
lemia with high LDL-C. Patients with the mutation also
ad a 14-fold increase in risk for CAD events, but in the
ntire study sample (cases and controls), only 10 subjects
ad CAD events, leading to a very wide confidence interval
or the odds ratio (2.3 to 87.1). Although risk for premature
AD events was increased, it is not possible to conclude
rom the data presented whether this mutation confers the
ame degree of risk for premature ASCVD events as does
amilial hypercholesterolemia. Despite the limitation of
ample size, the consistency of the results suggests that the
resence of the mutation does indeed confer a higher risk
or ASCVD.
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October 6, 2004:1436–8 Editorial CommentThe investigators demonstrate the power of combining
enotyping with careful phenotyping to provide more com-
elling evidence that the genetic mutation contributes to
SCVD. They began by identifying 94 individuals with a
ell-defined phenotype, HDL-C that is less than the fifth
ercentile for age and gender, which can easily be measured
uantitatively with standard assays. After identification of a
utation associated with low plasma levels of HDL-C and
po A-I, they not only examined the association between
enotype and the phenotype of low HDL-C, but they also
sed noninvasive imaging measures (FMD and IMT) that
rovide quantitative information on vascular structure and
unction. Finally, they examined whether there was an
ssociation between the genotype and clinical evidence of
remature CAD. This approach of careful quantitative
henotyping using both plasma measurements and vascular
maging modalities provides important evidence for under-
tanding how genetic mutations in metabolic pathways lead
o atherosclerosis and also suggests that the clinical efficacy
f therapies that target the identified metabolic pathways
ay be monitored by using quantitative plasma measure-
ents (biomarkers) and quantitative vascular imaging mo-
alities.
A different mutation in APOAI, in which cysteine is
ubstituted for arginine at position 173, was first noted in a
amily from Limone sul Garda, Italy, and was associated
ith low levels of HDL-C (15 mg/dl) but not with any
vidence of clinical atherosclerosis. This mutation, known as
po A-IMilano, allows for formation of disulfide bonds with
ther apo A-IMilano particles and with apo A-II, with more
apid metabolism than normal apo A-I particles (9). Carotid
MT in patients with apo A-IMilano is not increased despite
he profoundly reduced levels of HDL-C (10).
In addition to mutations that are associated with reduced
evels of HDL-C, clinical studies focusing on individuals
ith high levels of HDL-C have identified mutations or
olymorphisms in the gene encoding CETP. Mutations
eading to CETP deficiency are associated with increased
evels of HDL-C and apo A-I, but studies are conflicting as
o how this may influence the risk for CAD. However,
enetic variants have been associated with reduced activity,
ncreased HDL-C, reduced risk for CAD (11), and in-
reased longevity (12).
Data from genetic and metabolic studies have been used
o build a paradigm in which increased concentrations of
therogenic particles (as observed in mutations in the LDL
eceptor, apo B, and apo E) lead to lipoprotein deposition in
rteries with development and progression of atherosclero-
is, whereas high levels of HDL prevent or reverse athero-
clerosis. The development of novel pharmacologic thera-
ies has allowed clinical trials to test this paradigm. In the
ecently reported Apo A-I Milano Trial, patients with acute
oronary syndromes who received five weekly infusions of
ecombinant apo A-IMilano/phospholipid complex, an HDL
imetic, had modest but statistically significant regressionf coronary atherosclerosis as measured by intravascularltrasound (13). Although this was a small study
n  47 completed) with brief duration (5 weeks), the
esults suggesting that modulation of HDL-C levels may
nhance regression of atherosclerosis differ from the results
f clinical trials with statins, which primarily lower athero-
enic particles. Multiple clinical trials using quantitative
oronary angiography and now intracoronary ultrasound
ave shown that statins can stop or slow atherosclerosis but
o not on average lead to regression of the lesion or
mprovement in lumen diameter.
In follow-up to the Apo A-I Milano Trial, several
ompounds are being tested in animals and humans, such as
econstituted HDL (14), phospholipid liposomes in unila-
ellar vesicles (15), and orally administered apo A-I mi-
etic peptides (16). Another approach, the inhibition of
ETP, also is in clinical development, with one agent,
orcetrapib, showing marked increases in plasma levels of
DL-C (17) Several agonists of peroxisome proliferator-
ctivated receptors (PPARs) alpha, gamma, and delta that
aise HDL-C are also under development. Several agents,
uch as niacin, fibrates, and PPAR gamma agonists, raise
DL-C and are currently available.
The era of noninvasive interventions for CAD began
ith statins and other lipid-lowering therapies that promote
tabilization of lesions and stop the progression of athero-
clerosis. If therapies that modulate HDL indeed provide
dditive benefit to statin therapy and promote regression of
therosclerosis, we may soon enter into the era of noninva-
ive angioplasty. However, the new targets of pharmacologic
herapy identified by genetic studies must still pass rigorous
esting in clinical trials to assess not only the effects on
therosclerosis but also, ultimately, the benefits on reducing
ardiovascular events without substantially increasing risk
or adverse events.
eprint requests and correspondence: Dr. Christie M. Ballantyne,
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